de novo minibinders unlocking target access: NovoBinders
Generative AI with judgment.
Models propose; our sift decides.
NovoFy is built to design minibinders for the most difficult targets: the novel epitopes, the GPCRs, and the immunization-impossibles.
Through NovoFlow, we design, screen, and validate generated designs at the bench, as either therapeutic candidates or critical reagents.
The platform
Models designed for workflow flexibility.
Our sift decides what’s worth validating.
NovoFlow’s foundation models produce candidates. Then, our proprietary sift cuts them down. The sift is where our judgment lives.
It encodes what has actually expressed, folded, and worked at the bench, not just what scores well in silico.
The proof
60+
targets designed against
12,000+
in silico validated NovoBinders
Zero shot
more than 1 in 10 candidates meet design goals
Get started
2 ways to work with us.
Therapeutics
Surrogate molecules, therapeutic candidates and co-development. A conversation-led collaboration.
Reagents
Research, diagnostics and assay development. Defined scope, quoted from a structured request. A more self-serve path.
The team
The people behind the work.
NovoFy’s founders bring 30+ years of combined protein engineering experience from Amgen, Gilead, and BioGlyph, with a focus on GPCRs, multispecific antibodies, and other hard targets.
Our Scientific Advisory Board adds experience scaling AI at Google DeepMind and advancing drugs from discovery into late-stage clinical development.
We are small and technical by design. The scientist who scopes your project is the one who runs it.
Co-founder and CEO. Structural biology.
Co-founder and CTO. NovoFlow lead.
Scientific Advisory Board. Director of Engineering, Google DeepMind.
Scientific Advisory Board. Chief Scientific Officer, Equillium.
News
What’s happening at NovoFy.
Let’s get in touch.
Book a call or go straight to the intake form.